Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
A macrocycle-based therapy enters the clinic, as do projects targeting p53 interaction and IL-12.
An accelerated approval looks off the table, as the group’s first-line melanoma trial continues.
The NMPA has refused to back PFS, plus subgroup OS analyses, in fruquintinib’s stomach cancer study.
Duelling pivotal trials of anti-TROP2 ADCs should yield their first data imminently.
A US adcom will next month try to unravel confusion about PD-L1 status in first-line gastric cancer.
It’s back to school for biotech, with a packed conference schedule.